



December 11, 2020

Santen to Present Latest Data on MicroShunt  
at 14<sup>th</sup> EGS Congress

Santen Pharmaceutical Co., Ltd. (Head Office in Osaka) announced today that some publications related to the glaucoma surgical device, MicroShunt will be presented at the European Glaucoma Society's annual meeting (14<sup>th</sup> EGS Congress, <http://egs2020.org/>) from December 12 to 13, 2020.

MicroShunt (development code: DE-128, STN20001) has been launched in Europe as *PRESEFLO MicroShunt*. In the United States, the United States Food and Drug Administration (FDA) accepted the Premarket Approval (PMA) application for it for review in July, 2020. In this conference, two-year data from clinical studies outside the United States is published.

For abstracts, please see the following link;

[http://egs2020.org/sites/default/files/documenti/EGSbruxelles\\_ABSTRACT\\_BOOK.pdf](http://egs2020.org/sites/default/files/documenti/EGSbruxelles_ABSTRACT_BOOK.pdf)

Presentation topics related to MicroShunt

Session number	Presentation title
P049 / ePoster	One-year safety and effectiveness of MicroShunt implantation versus trabeculectomy across five European sites
P299 / ePoster	Effect of lens status at baseline on surgical outcomes following MicroShunt implantation in patients with primary open-angle glaucoma: a 2-year pooled analysis
P307 / ePoster	Outcomes of bleb needling in patients with primary open angle glaucoma implanted with the MicroShunt

Contact:

Investor Relations Group

Santen Pharmaceutical Co., Ltd.

E-mail: [ir@santen.com](mailto:ir@santen.com)